Skip to main content

NextImmune to benefit from Venture Kick financing

| News

NextImmune to benefit from Venture Kick financing


The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from the University of Basel is working on the development of selective immunosuppressive drugs. The fresh capital injection will facilitate preclinical development work at NextImmune.

Dr. med. Rajesh Jayachandran, Chief Scientific Officer and co-founder of NextImmune (img: NextImmune)

This year, Venture Kick is planning to support projects initiated by startups that open up access to the global markets for scientific organizations in Switzerland to the tune of 6.1 million Swiss francs overall, further details of which can be found in a press release issued by the startup accelerator based in Schlieren in the canton of Zurich. NextImmune can now look forward to banking a total of 150,000 Swiss francs from this pot. The spin-off from the University of Basel will put this financing towards developing a new generation of immunosuppressive therapies.

The Basel-based startup is working on the development of selective immunosuppressive drugs that protect against autoimmune diseases and transplant rejection without also compromising the immune response the human body requires to defend against infections and cancers. The financing should now enable NextImmune to carry out further preclinical development, the press release states. “The financial support, business insights, access to a smart pool of diversely talented individuals together with the overall experience gathered from our Venture kick journey will be instrumental for the follow-up fundraising activities of NextImmune”, explains Rajesh Jayachandran, Chief Scientific Officer and co-founder of NextImmune, in the press release.

BaseLaunch also supports NextImmune

NextImmune’s therapeutic approach is intended to help patients suffering from immunological or autoimmune diseases. The startup is also expecting interest from biotech and pharmaceutical companies that could market such an approach under a licensing agreement, Venture Kick writes in the press release. NextImmune is also supported by BaseLaunch. The biotech accelerator from the investment and innovation promotion agency Basel Area Business & Innovation included the startup in its portfolio in June of last year.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.